Envestnet Portfolio Solutions Inc. Raises Position in Danaher Corporation $DHR

Envestnet Portfolio Solutions Inc. increased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 4.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,933 shares of the conglomerate's stock after buying an additional 3,436 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Danaher were worth $15,592,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. MGO One Seven LLC increased its holdings in shares of Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after acquiring an additional 20,813 shares in the last quarter. Chicago Capital LLC grew its position in Danaher by 11.6% during the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate's stock worth $2,634,000 after purchasing an additional 1,391 shares during the last quarter. UniSuper Management Pty Ltd grew its position in Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock worth $34,954,000 after purchasing an additional 2,667 shares during the last quarter. Asahi Life Asset Management CO. LTD. acquired a new position in Danaher during the 1st quarter valued at approximately $539,000. Finally, Horizon Financial Services LLC raised its holdings in shares of Danaher by 20,400.0% in the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock worth $1,681,000 after buying an additional 8,160 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research analyst reports. Redburn Partners set a $220.00 price objective on shares of Danaher in a report on Wednesday, October 8th. Guggenheim reissued a "buy" rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Wells Fargo & Company reduced their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Robert W. Baird upped their target price on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Finally, Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $244.60.

Danaher Stock Up 1.4%

Shares of DHR stock opened at $205.36 on Tuesday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41. The stock has a market cap of $147.05 billion, a P/E ratio of 43.69, a P/E/G ratio of 2.88 and a beta of 0.77. The stock has a 50 day moving average of $200.82 and a 200 day moving average of $197.06. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher's payout ratio is presently 27.23%.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 11.20% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.